[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 13, Issue 3 (Summer 2022) ::
Caspian J Intern Med 2022, 13(3): 484-489 Back to browse issues page
Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
Saeideh Salehizadeh , Roghayeh Saeidi , Mohammad Ali Sahraian , Hossein Rezaei Aliabadi , Seyedeh Nafiseh Hashemi , Sharareh Sharareh , Mohammad Reza Gheini , Shaghayegh Shahmirzaei , Mahsa Owji , Abdorreza Naser Moghadasi *
Department of Neurology, Sina Hospital, Tehran University of Medical Sciences; Tehran; Iran , abdorrezamoghadasi@gmail.com
Abstract:   (1617 Views)
Background: The present study aimed to address the effect of Rituximab on the cognitive impairment in patients with secondary progressive MS (SPMS).
Methods: The present interventional study used a convenience sampling method to select the study participants from SPMS patients. All these patients had progressive disability over the last two years before being admitted in the study. Prior to the administration of Rituximab, the minimal assessment of cognitive function in the multiple sclerosis (MACFIMS) test was performed for each patient who was a candidate to be included in this study. This test was repeated by passing 6 and 12 months from the initial treatment with Rituximab. Since the data needed for this study were obtained at different time intervals, so a linear mixed model was used for their analysis. Analysis of variance (ANOVA) was also used to investigate whether time and sex generally affect the cognitive impairments in SPMS patients. A p-value <0.05 was considered as statistically significant in this study.
Results: Of the total 35 patients, 34% and 66% were men and women with a mean age of 41.33 and 41.39 years old, respectively. Rituximab showed a significant positive effect on a number of subgroups of MACFIMS test, including Controlled Oral Word Association Test (COWAT) (P-value: 0.038) and Brief Visuospatial Memory Test (BVMT-total) (P- value: 0.019).
Conclusion: The present study revealed that Rituximab has a positive effect on the cognitive impairment resulted from MS in secondary progressive patients.
Keywords: Secondary Progressive Multiple Sclerosis (SPMS), Rituximab, MACFIMS, Cognitive impairment
Full-Text [PDF 244 kb]   (539 Downloads)    
Type of Study: Original Article | Subject: Neurology
Received: 2021/02/28 | Accepted: 2021/06/30 | Published: 2022/06/1
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salehizadeh S, Saeidi R, Sahraian M A, Rezaei Aliabadi H, Hashemi S N, Sharareh S, et al . Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis. Caspian J Intern Med 2022; 13 (3) :484-489
URL: http://caspjim.com/article-1-2788-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 3 (Summer 2022) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4624